<p>Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferation of keratinocytes and immune dysregulation, leading to erythematous, scaly plaques. Conventional treatments, including corticosteroids, immunosuppressants, and biologics, often present challenges such as systemic side effects, poor skin penetration, and reduced patient compliance. Lipid nanocarriers (LNCs) have emerged as promising drug delivery systems for psoriasis management, offering enhanced drug stability, targeted delivery, improved skin penetration, and controlled drug release. This review explores the advancements in LNC-based formulations, including solid lipid nanoparticles, nanostructured lipid carriers, liposomes, and ethosomes, highlighting their advantages over traditional therapies. The physicochemical properties, mechanisms of skin penetration, and therapeutic efficacy of LNCs in psoriasis treatment are discussed, along with preclinical and clinical findings. The integration of lipid nanocarriers into psoriasis treatment regimens holds significant promise for improving patient outcomes by providing more effective and safer therapeutic alternatives.</p> Graphical Abstract <p></p>